Literature DB >> 9427718

The metastatic characteristics of murine lymphoma cell lines in vivo are manifested after target organ invasion.

F Aoudjit1, E F Potworowski, Y St-Pierre.   

Abstract

The ability of a tumor cell to survive is critical for successful dissemination to sites distant from the primary tumor. Tumor cells must enter blood circulation, resist hemodynamic shear stress of the blood circulation, successfully extravasate, and then migrate through dense tissue stroma to a site favorable for tumor growth. Some tumor cells must therefore be endowed with peculiar abilities to successfully metastasize, whereas others, although capable of forming tumor in specific organs, cannot metastasize. This property has often been associated with the homing ability of a given tumor cell, likely through the expression of organ-specific homing receptors that are critical for the extravasation process. The present work was aimed at establishing the point at which metastatic and nonmetastatic lymphoma cells diverge. Although 164T2 and 267T2 lymphoma cell lines can successfully form thymic lymphoma when injected intrathymically, only the 164T2 clone can efficiently form tumor in kidneys, spleen, and liver after intravenous inoculation. Using the indium-labeling technique to monitor the homing kinetic of both cell lines, we showed that the critical step for the successful metastasis of the lymphoma cell was determined in the final steps of the disseminating process, namely after homing. These results indicate that, whereas binding of tumor cells to vascular endothelium through specific adhesion mechanisms is a prerequisite for dissemination of tumor cells, the resistance of a tumor cell to the antagonist action of the host and/or its ability to grow tumor occurs only after homing to the target organ.

Entities:  

Mesh:

Year:  1998        PMID: 9427718

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Real-time detection of circulating apoptotic cells by in vivo flow cytometry.

Authors:  Xunbin Wei; Dorothy A Sipkins; Costas M Pitsillides; John Novak; Irene Georgakoudi; Charles P Lin
Journal:  Mol Imaging       Date:  2005 Oct-Dec       Impact factor: 4.488

2.  Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma.

Authors:  Zebin Wang; Yu Zheng; Hyun Jung Park; Jing Li; Janai R Carr; Yi-ju Chen; Megan M Kiefer; Dragana Kopanja; Srilata Bagchi; Angela L Tyner; Pradip Raychaudhuri
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

3.  Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.

Authors:  X Meng; N R Carlson; J Dong; Y Zhang
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

Review 4.  Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies.

Authors:  Md Salman Shakil; Mahruba Sultana Niloy; Kazi Mustafa Mahmud; Mohammad Amjad Kamal; Md Asiful Islam
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

5.  Expression and functions of galectin-7 in human and murine melanomas.

Authors:  Katherine Biron-Pain; Andrée-Anne Grosset; Françoise Poirier; Louis Gaboury; Yves St-Pierre
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

6.  Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.

Authors:  K Vanderkerken; C De Greef; K Asosingh; B Arteta; M De Veerman; I Vande Broek; I Van Riet; M Kobayashi; B Smedsrod; B Van Camp
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  Integrin signaling in cancer cell survival and chemoresistance.

Authors:  Fawzi Aoudjit; Kristiina Vuori
Journal:  Chemother Res Pract       Date:  2012-04-11

8.  Regulation of the chemokine receptor CXCR4 by hypoxia.

Authors:  Tiziana Schioppa; Badarch Uranchimeg; Alessandra Saccani; Subhra K Biswas; Andrea Doni; Annamaria Rapisarda; Sergio Bernasconi; Simona Saccani; Manuela Nebuloni; Luca Vago; Alberto Mantovani; Giovanni Melillo; Antonio Sica
Journal:  J Exp Med       Date:  2003-11-03       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.